Although there have been tensions in recent times over the balance between patent and plant variety rights, it seems that the EPO and CPVO are keen to continue with their formal co-operation.  

Recently, the European Commission has held that rulings by the EPO’s Enlarged Board of Appeal to allow claims to products obtained from an essentially biological process were contrary to the intentions of the Biotechnology Directive. This resulted in (controversial) amendments to Rules 27 and 28 EPC in order to exclude from patentability plants and animals exclusively obtained by essentially biological processes. 

Co-operation between the two offices responsible for complementary rights should be a positive way of ensuring consistency in practice.